Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
59.85
-0.15 (-0.25%)
At close: Dec 5, 2025
-5.38%
Market Cap 3.06B
Revenue (ttm) 724.20M
Net Income (ttm) 121.15M
Shares Out 51.15M
EPS (ttm) 2.37
PE Ratio 25.27
Forward PE 20.34
Dividend 0.94 (1.56%)
Ex-Dividend Date Jul 14, 2025
Volume 87,177
Average Volume 105,179
Open 60.10
Previous Close 60.00
Day's Range 59.85 - 60.90
52-Week Range 45.52 - 66.55
Beta 0.15
RSI 54.37
Earnings Date Feb 23, 2026

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,197
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements